कंपनी का अवलोकन
Zevra Therapeutics, Inc. operates as a commercial-stage biotechnology entity dedicated to resolving unmet medical needs for rare disease treatments within the United States market. The firm leverages its proprietary Ligand Activated Technology platform to develop and advance its product portfolio, with KP1077 serving as its lead product candidate consisting of KP1077IH. This organization functions within the broader Healthcare sector, specifically navigating the specialized Biotechnology industry where innovation in rare disease therapies is paramount. The company currently maintains a market capitalization of $563.04M and generates annual revenue of $106.47M, supported by a workforce of 61 employees. These financial metrics indicate a mid-cap biotechnology enterprise that has achieved significant commercial traction despite operating in a niche therapeutic area, suggesting a substantial market position relative to early-stage peers but still requiring capital efficiency to sustain R&D and commercial expansion efforts.
वित्तीय स्वास्थ्य
Zevra Therapeutics reported revenue of $106.47M and net income of $77.58M over the trailing twelve months, while reporting an EBITDA of $-179,000. The substantial discrepancy between the high net income and the near-zero EBITDA reveals a cost structure heavily influenced by non-operating income or one-time gains, as operating expenses appear to be offset by significant other income sources to generate profitability despite minimal earnings before interest, taxes, depreciation, and amortization. The company recorded a free cash flow of $-1,955,250, which indicates a temporary cash outflow typical for biotechnology firms investing in commercialization activities, though the strong net income suggests operational cash generation capabilities beyond the immediate cash flow statement. The gross margin stands at 84.5%, reflecting high pricing power and low cost of goods sold inherent in biotechnology manufacturing. The operating margin is reported at 27.3%, indicating efficient management of operational expenses relative to sales, while the profit margin reaches 78.2%, demonstrating exceptional bottom-line profitability driven by non-operating factors. In terms of leverage, the company holds $191.01M in cash against $63.21M in debt, resulting in a debt-to-equity ratio of 40.87. Although the debt-to-equity figure appears elevated numerically, the abundant cash reserves provide a conservative balance sheet profile where debt obligations are easily covered by liquid assets. The current ratio of 5.68 signifies robust short-term liquidity, ensuring the firm can meet its obligations well beyond the standard year without immediate refinancing risks. Return on Equity is 85.7%, highlighting exceptional returns generated on shareholders' capital, whereas Return on Assets is -1.1%, which is anomalous in this context and likely stems from the same non-operating income distortions affecting the EBITDA metric, complicating the assessment of asset utilization efficiency.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is 7.10, while the forward P/E is projected at 6.31. The difference between these metrics implies that the market expects earnings to grow or that the forward estimate incorporates anticipated changes in the non-operating income streams that currently inflate the current earnings. The price-to-book ratio stands at 3.53, indicating that the market values the company at a significant premium over its net asset book value, reflecting confidence in its intellectual property and future commercial potential. Alternative valuation metrics show a price-to-sales ratio of 5.29 and an EV/EBITDA of -2431.50; the negative EV/EBITDA suggests that traditional enterprise value multiples are distorted by the unusual earnings composition, making price-to-sales a more relevant metric for comparing revenue generation efficiency against peers. The stock has a 52-week high of $13.16 and a 52-week low of $6.19. Without the current share price explicitly provided in the source data, the relative trading position cannot be calculated as a percentage; however, the range of $6.97 in width demonstrates the volatility experienced over the last year. The beta value is 0.89, which indicates that the stock's price volatility is slightly lower than the broader market, suggesting it is less sensitive to general market fluctuations compared to the S&P 500.
Growth & Income
Revenue growth year-over-year is 183.4%, while earnings growth is listed as N/A due to the unique composition of net income relative to EBITDA. The absence of a traditional earnings growth rate compared to the explosive revenue growth implies that the company's profitability is currently driven by factors other than core operating leverage, such as investment income or specific accounting adjustments. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the firm retains all earnings and reinvests them into research, development, and commercialization activities rather than distributing capital to shareholders. This growth-oriented strategy is consistent with the capital-intensive nature of the biotechnology industry where internal funding supports pipeline advancement. The overall growth and income profile is characterized by rapid revenue expansion coupled with non-dividend distribution, positioning the company as a pure play growth investment dependent on future product approvals and sales performance.